Autologous Matrix-induced Chondrogenesis Market By Material Type (Hyaluronic Acid, Polyethylene glycol (PEG), Collagen, Polylactic-co-glycolic Acid, Others), By Application (Knee Cartilage Repair, Elbow Cartilage Repair, Hip Cartilage Repair, Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers (ASCs)), and Geography.
Autologous Matrix-induced Chondrogenesis Market size was valued at 97.43 million in 2021 and is expected to reach 173.57 million by 2028, at a CAGR of 8.6% during the forecast period 2022 to 2028. Autologous matrix-induced chondrogenesis is single step cartilage restoration process that helps to repair the articular cartilage damage. In this process, the micro fracture is combines with the bi-layer collagen I/III. Â Membrane. AMIC is developed for the treatment of osteochondral and traumatic chondral lesions to establish the first line treatment. The AMIC slows down the cartilage degeneration to delay or avoid the partial or total joint replacement surgery.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the geriatric population more prone for bone and joint disorders is a key factor drives the global autologous matrix-induced chondrogenesis market. Moreover, rise in number of sports injuries, increase in the preference for minimally invasive surgical procedures, less post-operative complications and lower cost compared with conventional surgeries, increasing in the R&D for the advancement in AMIC, rise in disposable income, and increase in the awareness about AMIC in developed and emerging countries are anticipated to surge the global autologous matrix-induced chondrogenesis market over the forecast years. However, lack of favorable reimbursement policies and dearth of skilled professionals and clinical date are restrain the growth of autologous matrix-induced chondrogenesis market over the forecast timeframe.
Geographically, global autologous matrix-induced chondrogenesis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America autologous matrix-induced chondrogenesis market is poised to grow due to rise in prevalence of bone and joint disorders, increase in R&D activities by market players, and sophisticated healthcare infrastructure are bolster the market. Europe autologous matrix-induced chondrogenesis market is driving by rise in demand for minimally invasive surgical procedures, presence of skilled professionals in developed countries, and increase in number of sports injuries are surge the market. Asia Pacific autologous matrix-induced chondrogenesis market has prominent share attributed to increase in the medical tourism in Asia Pacific countries, rise in disposable income, and large patient pool in Asia Pacific region are fuel the market.
Latin America
Europe
Asia Pacific
Middle East
North America
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.